News for Healthier Living

Precision Breast Cancer Trial Shows Improved Treatment by Tumor Subtype

Recent results from one of the I-SPY 2.2 study arms, published September 14, 2024 in Nature Medicine, showed that neoadjuvant treatment with the antibody-drug conjugate datopotamab-deruxtecan (Dato-DXd) in combination with the immune checkpoint inhibitor, durvalumab (Imfinzi), produced high rates of pCR in patients who have an immune breast cancer subtype as well as a subtype of triple negative cancer that would ordinarily have a high risk of recurrence.

October 1, 2024


October 5 2024

October 4 2024

October 3 2024

October 2 2024

October 1 2024

September 30 2024

September 29 2024

September 28 2024

September 27 2024

September 26 2024

September 25 2024

September 24 2024

September 23 2024

September 22 2024

September 21 2024